TB Alliance Joins Indonesia’s High-Level Meeting on TB
BALI, Indonesia (November 11, 2024)—TB Alliance is honored to join today’s High-Level Meeting hosted by the Indonesian Ministry of Health.
Featured News
New Clinical Trial Examines Use of Novel Compound Telacebec in Buruli Ulcer Patients
NEW YORK (August 21, 2024) – In July 2024, a Phase 2 proof-of-concept study was initiated to explore the use
New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World
MANILA (25 March 2024)—TB Alliance’s new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding
Commitment, Innovation and Action are Needed to End TB — On World TB Day, We Reaffirm our Dedication to all Impacted by Tuberculosis
NEW YORK (March 24, 2024)—Today is World TB Day, the anniversary of when, in 1882, Dr. Robert Koch announced his
World Leaders Cite the Benefit and Importance of New, Six-Month Drug-Resistant TB Treatment at United Nations High-Level Meeting on Tuberculosis
The 2023 United Nations (UN) High-Level Meeting (HLM) on Tuberculosis (TB) saw world leaders come together to commit to increased
UN Commitment on Tuberculosis Needs Leadership to Match Ambition
TB Alliance wholeheartedly supports the commitment made today at the United Nations High-Level Meeting on Tuberculosis (TB) to fight this
Realizing our “Triple-A Mandate”
Four years ago, TB Alliance secured the first regulatory approval from the United States Food and Drug Administration (US FDA)
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
19 December 2022: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the
New Study: Recently Approved Drug-Resistant TB Treatments Can Save National Governments up to US$740 Million Annually
PRETORIA (16 November, 2022)—A new study published in PLOS Global Public Health found that the BPaLM/BPaL treatment regimen that will
Drug-Resistant TB Trial Results Published in New England Journal of Medicine
Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of